Rapid diagnostic kits
Rapid diagnostic kits are commonly referred to as RDTs. Based on the detection of a particular disease we can modify the test strategy and design.
Currently there are two main types of kit available in the market
-
Test that detects pathogenic antigens in the target organ of host (antigen based).
-
Test that detects host antibodies produced in response to the pathogenic infection (Serological antibody-based).
Knowing the limitations of a serological test, experts believe that “Serologic tests can improve early diagnosis of COVID-19. Because of the high false-negative rates with PCR, serologic tests will be a useful supplement to RNA detection [1-3].
​
Current R&D pipeline
​
1. SARS-Cov-2 RDTs
We are currently manufacturing SARS-Cov-2 rapid diagnostic serological antibody-based tests that demonstrate far superior sensitivity and specificity than other products available in the market. These kits are ready to manufacture and have USFDA manufacturing approval through Boston Molecules Inc. USA.
​
2. Breast cancer rapid diagnostic kits
This product is currently being developed. We have previously published data providing useful biomarkers that can be used for the early detection of all kinds of breast cancer. This product is in the early stages of development [4, 5].
​
3. High-tech Personal Protective Equipment
The company is also currently conducting early-stage R&D into the development of a high-tech positive pressure biohazmat suits. These suits can be used by first responders at the site of a highly infectious pathogenic outbreak for containment and prevention.
​
​
[1] Guo L et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis 2020 Mar 21; [e-pub]. (https://doi.org/10.1093/cid/ciaa310)
[2] Zhao J et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis 2020 Mar 28; [e-pub]. (https://doi.org/10.1093/cid/ciaa344)
[3] Li Z et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol 2020 Feb 27; [e-pub]. (https://doi.org/10.1002/jmv.25727)
[4] Venkatrao Nunna, Nasir Jalal, Matthias Bureik.* (2017) Anti- CYP4Z1 autoantibodies detected in breast cancer patients. Cellular & Molecular Immunology 14:1–3. doi:10.1038/cmi. 2017.21, Nature publishing group. http://www.nature.com/cmi/journal/vaop/ncurrent/full/ cmi201721a.html
[5] Nasir Jalal*, Jing Wei, Yaxin Jiang, Janak L. Pathak, Austin R. Surendranath, Chang Y. Chung. (2019) Low dose Bisphenol A exposure initiates tumorigenic events. Cogent Medicine. 6: 1616356. https://doi.org/10.1080/2331205X.2019.1616356